Skip to main content
Utility Menu
Patients
Investors
Newsroom
Contact Us
Regional Navigation
Global Sites
Switzerland
Deutsch
English
Français
Italiano
UK
English
United States
English
Toggle Menu Button
Utility Menu
Patients
Investors
Newsroom
Contact Us
Regional Navigation
Global Sites
Switzerland
Deutsch
English
Français
Italiano
UK
English
United States
English
Social Links
Twitter
LinkedIn
Instagram
Facebook
Main navigation
Our Disease Areas
Duchenne Muscular Dystrophy
Limb-girdle Muscular Dystrophy
Charcot-Marie-Tooth Disease
Our Science
Gene Therapy Engine
RNA Platform
Gene Editing
Manufacturing
Strategic Partnerships
Investigator-Initiated Studies
Our Products & Pipeline
Products
Pipeline
Clinical Trials
Treatment Access
About Us
Leadership
Patient Affairs
Corporate Responsibility
Grants & Giving
Global Locations
Contact Us
Join Us
Career Opportunities
Toggle Menu Button
Search
Sarepta Therapeutics Announces Positive Vote from U.S. FDA Advisory Committee Meeting for SRP-9001 Gene Therapy to Treat Duchenne Muscular Dystrophy
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics Announces First Quarter 2023 Financial Results and Recent Corporate Developments
Sarepta Therapeutics to Announce First Quarter 2023 Financial Results
Pagination
First page
« First
Previous page
‹ Previous
…
Page
36
Page
37
Page
38
Page
39
Page
40
Page
41
Page
42
Page
43
Current page
44
